Prediction of polygenic risk of heart attacks in Asians enabled by whole genome sequencing

Intensive treatment of Asian genetic variants allows identification of individuals at risk of heart attack

San Francisco, California, United States, September 14, 2022 / – US and Hong Kong-based Rainbow Genomics has launched an assessment of heart attack risk in Asian individuals using complete genome sequencing data. The test is particularly useful for confirming a higher lifetime risk of myocardial infarction in asymptomatic individuals.

This polygenic test is based on genetic variants specific to Asia. These genetic variants have been meticulously coordinated by Rainbow clinical teams, using public and unpublished data, and have been successfully replicated in multiple international studies using more than 40,000 affected patients and matching controls over the past 15 years. These genetic variants are suitable for risk assessment for East Asians, including Chinese, Japanese and Koreans.

Genotypes are analyzed based on patients’ whole-genome sequencing test data, and associated risk calculations are performed using standard statistical tools. The predictive power is sufficient to identify a subset of the East Asian population most likely to be at risk of heart attack. In addition, single-gene mutations associated with dysfunction of the cardiovascular system, identified by whole genome sequencing, will also be used. Based on both unigene and polygenic variants, the resulting lifetime risk assessment will provide an additional factor that is complementary to traditional risk factors such as low-density lipoprotein (LDL) level, blood pressure, age and sex. The Heart Attack Risk Assessment Report is now part of the results reported in the Rainbow Genomics Adult 6000 (TM) and Adult 8000 (TM) tests for whole-genome sequencing.

About the rainbow test for whole genome sequencing

The test provides five clinical reports:

1. Personal health assessment

• crabs
• Cardiovascular disorders
• Endocrine system dysfunction, including diabetes and fatty liver
• Sleep disorders
• Hearing and eye disorders
• Skeletal and orthopedic disorders
• Immune system disorders
Abnormalities of the skin
Autoinflammatory disorders
• behavioral anomalies
• Neurological disorders including dementia and Alzheimer’s disease

2. Reproductive health assessment

• Male sterility
• Infertility in women

3. Complete genome carrier status

• Carrier screening analysis for disorders recommended by the American College of Obstetricians and Gynecologists and the American College of Medical Genetics

• Whole-genome vector analysis – mutations in 2,500 genes associated with recessive disorders that can be passed on to the patient’s children

4. Common disease risk assessment

Common complex diseases such as diabetes, heart attack and stroke are mainly caused by changes in multiple genetic variants (polygenic risk). However, these variants are highly ethnically specific. Polygenic risk assessment for specific ethnic groups such as Asians is challenging because there are very few publications using Asian patients and statistically significant healthy controls available.

• Rainbow Genomics’ expert sponsored polygenic variants are highly race-specific and supported by large-scale genomic association studies and replication studies using tens of thousands of patients and controls en masse from Asia, the United States, and European countries.

5. Pharmacogenomic evaluation of 185 drugs to improve clinical outcomes

• For chronic disorders, achieving risk reduction goals through improved medication adherence is critical. Pharmacogenetic evaluation enables high therapeutic efficacy by reducing side effects of drugs, which leads to better therapeutic outcomes.

About Rainbow Genomics

rainbow genomics ( to provide clinically proven genomic and proteomic assays for Asian, Caucasian, mixed, and indigenous minorities. The company offers clinicians high diagnostic success, enabling timely treatment of patients who can benefit from immediate medical interventions.

Using a multi-platform approach, including proteomics, whole genomes, whole exomes, RNA, long reads, methylation, single-cell sequencing, Sanger sequencing, high-resolution microarray testing, high-density DNA array genotyping, and by international kit In collaboration, Rainbow Genomics delivers diagnostic productivity that meets or exceeds the highest standards reported by leading US and European medical institutions.

All Rainbow Genomics testing is performed in highly complex clinical laboratories that are CLIA-certified and CAP-accredited. Patient privacy is protected through Rainbow’s HIPAA compliant clinical testing process.

Daniel Siew
rainbow genome
+852 3481 0977